Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?

Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker? Opinion EDITORIAL Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker? Van Morris, MD; Arvind Dasari, MD, MS; Scott Kopetz, MD, PhD The ability to optimize adjuvant chemotherapy recommenda- add extra complexity when deployed for routine clinical care, which contrast with other tumor-agnostic panel approaches tions for patients with resected colorectal cancer (CRC) has been historically limited by the use of clinicopathologic characteris- in development. It remains to be seen which strategy will tics, which imperfectly prognosticate the risk for recurrence. In have the optimal combination of sensitivity, specificity, and patients with stage II CRC, simplicity in clinical deployment. variation exists among on- From the results reported by Wang and colleagues, 58 pa- Related articles pages 1118 and cologists, in the absence of a tients with stages I to III CRC were followed up after surgical biomarker with demonstrated resection for ctDNA status. Circulating tumor DNA positivity survival benefit, in the decision to administer adjuvant was present postoperatively in 11 (28%) of the 40 patients who chemotherapy. One approach to identifying patients with re- proceeded to surveillance without adjuvant chemotherapy and sected CRC at higher risk of recurrence that has shown great in 2 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?

Morris, Van; Dasari, Arvind; Kopetz, Scott
JAMA Oncology , Volume 5 (8) – Aug 9, 2019
Download PDF
3 pages

Loading next page...
 
/lp/american-medical-association/can-circulating-tumor-dna-in-early-stage-colorectal-cancer-be-more-Te5DU5fQIG

References (14)

Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2019.0503
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker? Van Morris, MD; Arvind Dasari, MD, MS; Scott Kopetz, MD, PhD The ability to optimize adjuvant chemotherapy recommenda- add extra complexity when deployed for routine clinical care, which contrast with other tumor-agnostic panel approaches tions for patients with resected colorectal cancer (CRC) has been historically limited by the use of clinicopathologic characteris- in development. It remains to be seen which strategy will tics, which imperfectly prognosticate the risk for recurrence. In have the optimal combination of sensitivity, specificity, and patients with stage II CRC, simplicity in clinical deployment. variation exists among on- From the results reported by Wang and colleagues, 58 pa- Related articles pages 1118 and cologists, in the absence of a tients with stages I to III CRC were followed up after surgical biomarker with demonstrated resection for ctDNA status. Circulating tumor DNA positivity survival benefit, in the decision to administer adjuvant was present postoperatively in 11 (28%) of the 40 patients who chemotherapy. One approach to identifying patients with re- proceeded to surveillance without adjuvant chemotherapy and sected CRC at higher risk of recurrence that has shown great in 2

Journal

JAMA Oncology – American Medical Association

Published: Aug 9, 2019

There are no references for this article.